Showing 1,522 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Injectable & long-acting PrEP

MSF: ViiV must make groundbreaking HIV prevention injection affordable and available

Editor's pick
MSF
29 November 2022
Access to healthcare

2022 HIV Market Report: The state of the HIV market in low- and middle-income countries

Editor's pick
Clinton Health Access Initiative
17 November 2022
Finance & funding

Good news: South African HIV medicine prices have decreased dramatically!

Editor's pick
GroundUp
17 November 2022
Pharmaceutical industry

Index finds more pharma companies moving to address access to medicine. Will they now go further?

Editor's pick
Access to Medicine Foundation
17 November 2022
Injectable & long-acting PrEP

Delays in global, affordable access to long-acting, injectable HIV medicines would cost lives, say AIDS campaigners

Editor's pick
UNAIDS
17 November 2022
Access to healthcare

UK–India trade deal could “jeopardise” generic medicines

Editor's pick
The Lancet (requires free registration)
12 November 2022
Pharmaceutical industry

Gilead wins HIV patent manipulation suit but AIDS health group to appeal

Editor's pick
FiercePharma
11 November 2022
Pharmaceutical industry

Long-suffering CytoDyn withdraws HIV approval application for leronlimab, blaming clinical research organization

Editor's pick
FierceBiotech
1 November 2022
Injectable & long-acting PrEP

European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention

Editor's pick
ViiV press release
28 October 2022
UK health services

Making more of medicines in the drive to end new HIV infections

Editor's pick
NHS England
11 October 2022
People with limited treatment options

FDA Approves Trogarzo for 30-Second IV Push, Simplifying HIV Treatment for Heavily Treatment-Experienced People

Editor's pick
Infectious Disease Special Edition
5 October 2022
New & experimental HIV treatments

5 FDA decisions to watch in the fourth quarter

Editor's pick
BioPharma Dive
3 October 2022
Pharmaceutical industry

Under new leadership, CytoDyn ditches COVID-19 programs

Editor's pick
FierceBiotech
30 September 2022
Pharmaceutical industry

Gilead targets 'large-scale' HIV drugs counterfeiting scheme as judge orders asset freeze

Editor's pick
FiercePharma
30 September 2022
Access to healthcare

How a Danish Company Grabbed Control of the Monkeypox Vaccine

Editor's pick
The American Prospect
30 September 2022
New & experimental HIV treatments

Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP

News
23 September 2022
New & experimental HIV treatments

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
20 September 2022
The search for an HIV prevention vaccine

HIV Vaccine Still Years Away, Former AIDS Society Head Warns

Editor's pick
Bloomberg
15 September 2022
Pharmaceutical industry

Gilead settles patent fight with generic drugmakers over HIV drugs

Editor's pick
Reuters
13 September 2022
Access to healthcare

Counterfeit HIV Meds Are Endangering Some of America’s Most Vulnerable People

Editor's pick
VICE
12 September 2022
Pharmaceutical industry

Gilead must face pay-for-delay case over HIV drugs, judge rules

Editor's pick
Reuters
28 August 2022
New & experimental HIV treatments

European Commission approves first twice-yearly HIV medication

News
25 August 2022
HIV treatment

Best-in-class second-line HIV treatment rolls out in Zambia and Nigeria

Editor's pick
Clinton Health Access Initiative
25 August 2022
Injectable & long-acting HIV treatment

UNAIDS responds to EU approval of a long acting HIV treatment option: “To end AIDS, share technology.”

Editor's pick
UNAIDS
23 August 2022